Evidence map›Paper›PMID 39971294›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Post-Transplant Lymphoproliferative Disorder Which Developed 45 Years After Kidney Transplantation.

Nobuaki Nishima, Yoshifumi Hamasaki, Giyoung Kwoun, Yosuke Hirakawa, Akira Chiba, Yuki Horiguchi, Kensuke Fukuda, Masaomi Nangaku

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nobuaki NishimaDivision of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Japan.
Yoshifumi HamasakiDepartment of Hemodialysis and Apheresis, The University of Tokyo Hospital, Japan.
Giyoung KwounDivision of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Japan.
Yosuke HirakawaDivision of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Japan.
Akira ChibaDivision of Hematology, Graduate School of Medicine, The University of Tokyo, Japan.
Yuki HoriguchiDepartment of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo Hospital, Japan.
Kensuke FukudaDepartment of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo Hospital, Japan.
Masaomi NangakuDivision of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-transplant lymphoproliferative disorder (PTLD) affects from 0.8-2.5% of kidney transplant patients, with peaks in incidence within 1 year and 10-14 years post-transplant. Very late-onset PTLD (VL-PTLD) can occur over 10 years post-transplant, reportedly up to 30 years, but its characteristics remain unclear. A 61-year-old man developed PTLD 45 years after kidney transplant, presenting with fever and shortness of breath. Computed tomography revealed lung and liver masses and biopsy-confirmed stage IVB monomorphic PTLD. Despite obtaining an initial improvement, the patient died on day 66. VL-PTLD may differ from early- or late-onset PTLD, thus necessitating further research on both the associated risks and management.

Indexed as

Kidney TransplantationLymphoproliferative DisordersPostoperative ComplicationsFatal OutcomeHumansMaleMiddle AgedTime Factorsdiffuse large B-cell lymphoma (DLBCL)immunosuppressive agentskidney transplantationpost-transplant lymphoproliferative disorder (PTLD)very late onset PTLD (VL-PTLD)

Identifiers

PMID39971294
PMCPMC12425584

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.